Navigation Links
BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:5/16/2008

WOBURN, Mass., May 16 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEX GM-CSF in advanced metastatic melanoma is now available at the American Society of Clinical Oncology (ASCO) website located at http://www.asco.org. A summary of the abstract which describes the data as of the submission date to ASCO in January 2008 is provided below.

Senior clinical investigator, Neil N. Senzer, M.D., will present up-to-date results of the abstract entitled "Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpes virus in unresectable metastatic melanoma," at the 2008 ASCO Annual Meeting in Chicago, IL on Sunday, June 1 at 9:30am EDT during the melanoma conference session.

A summary of the abstract follows:

Background: OncoVEX GM-CSF is a second generation oncolytic herpes simplex virus (HSV) which encodes GM-CSF. OncoVEX GM-CSF had previously been shown to be well tolerated in a phase I clinical trial in patients with a range of tumor types, in which anti-tumor effects were seen in both injected and un-injected tumors.

Phase II Study Design: Single-arm monotherapy in up to 50 patients with unresectable stage IIIc/IV metastatic melanoma.

End Points: The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed upon with the FDA was to achieve two objective responses or stable disease >2 months.

Interim Results: At the time of the abstract submission, 40 patients had been enrolled of whom 31 were evaluable. 81% had stage IV disease. With respect to systemi
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... the following open letter to shareholders from President ... Sc. Dear RXi Shareholders, ... inaccurate statements posted on certain social media sites ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... former senior vice president and corporate controller, has been ... effective immediately, replacing Peggy Mulligan, former chief financial officer, ... other interests.  The Company has initiated a search to ...
... (Nasdaq: STXS ) announced today that the Company ... which includes a $30 million revolving facility that matures on ... matures on December 31, 2013.  The new facility was led ... that was scheduled to mature in March 2011. ...
Cached Medicine Technology:Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
(Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... effect , MONDAY, Oct. 5 (HealthDay News) -- Although ... this isn,t reason enough for most people to stop eating ... blood pressure due to methylmercury will never outweigh the benefits ... in the department of social and preventive medicine at Laval ...
... desired antibodies in some, but effects were fleeting, scientists say ... help cocaine addicts beat their habit is showing some effect ... more than one-third of participants in a new study developed ... this group, cocaine use did go down. But the effects ...
... New Delhi, Singapore and Washington DC (October 5, 2009) SAGE ... by Dr. Prem Reddy, founder and previous Editor-in-Chief of the ... field of cancer research is entering a new and exciting ... modern genetics are beginning to provide new clues into how ...
... Fewer secondary schools in the United States are selling ... according to a survey from the Centers for Disease Control ... in states that have adopted strong school nutrition standards and ... , The report, "Availability of Less Nutritious Snack Foods ...
... Mass., Oct. 5 Hologic, Inc. (Hologic or the ... and supplier of premium diagnostics, medical imaging systems and ... women, today announced plans to release its fourth quarter ... 2009 after market close. In conjunction with the release, ...
... Fred Hutchinson Cancer Research Center have been awarded 60 ... Recovery & Reinvestment Act of 2009. The totals reflect ... the National Institutes of Health. , The individual projects ... benefit every level of researcher at the Hutchinson Center, ...
Cached Medicine News:Health News:Mercury in Fish Linked to High Blood Pressure 2Health News:Mercury in Fish Linked to High Blood Pressure 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:SAGE launches Genes & Cancer 2Health News:Fewer U.S. Schools Selling Less Nutritious Food and Beverages 2Health News:Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday, November 9, 2009 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 3Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: